NDC 63323-241

Glycophos

Sodium Glycolate

Glycophos is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Fresenius Kabi Usa, Llc. The primary component is Sodium Glycerophosphate Anhydrous.

• Product ID: 63323-241_0b312fc3-1b52-4eb3-ac9b-8d22978d7d8b
• NDC: 63323-241
• Product Type: Human Prescription Drug
• Proprietary Name: Glycophos
• Generic Name: Sodium Glycolate
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2013-05-13
• Marketing Category: UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE / UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE
• Labeler Name: Fresenius Kabi USA, LLC
• Substance Name: SODIUM GLYCEROPHOSPHATE ANHYDROUS
• Active Ingredient Strength: 216 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2020-12-31

Packaging

NDC 63323-241-20

10 VIAL, PLASTIC in 1 CARTON (63323-241-20) > 20 mL in 1 VIAL, PLASTIC

• Marketing Start Date: 2013-05-13
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 63323-241-20 [63323024120]

Glycophos INJECTION, SOLUTION

• Marketing Category: Unapproved drug for use in drug shor
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2013-05-13

Drug Details

Active Ingredients

Ingredient	Strength
SODIUM GLYCEROPHOSPHATE ANHYDROUS	216 mg/mL

OpenFDA Data

• SPL SET ID: dcd92dc7-c6f9-4866-9edd-c95d5097c4e5
• Manufacturer:
  • Fresenius Kabi USA, LLC
• UNII:
  • YP1H63LJ2K
• RxNorm Concept Unique ID - RxCUI:
  • 1423812
  • 1423807